Ivadrabine for CHF

In this large placebo controlled trial of patients with CHF (EF<35%), they were randomized to ivadrabine or placebo, and the intervention group had significantly lower incidence of the primary outcome (CV death or hospitalized CHF) (24% vs 29% at about 2 year follow up). Although not yet approved by the FDA, once approved this drug will likely become a part of the drug cocktail for patients with systolic heart failure (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment